Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


American Journal of Health-System Pharmacy, Vol. 64, Issue 3, 273-275
Copyright © 2007 by American Society of Health-System Pharmacists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hilas, O.
Right arrow Articles by Charneski, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hilas, O.
Right arrow Articles by Charneski, L.

Case Report

Lamotrigine-induced Stevens-Johnson syndrome

Olga Hilas and Lisa Charneski

OLGA HILAS, PHARM.D., BCPS, is Assistant Clinical Professor, Clinical Pharmacy Practice; and LISA CHARNESKI, PHARM.D., BCPS, is Assistant Clinical Professor, Clinical Pharmacy Practice, St. John’s University, Queens, NY.

Address correspondence to Dr. Charneski at St. Albert’s Hall, Room 104, St. John’s University, 8000 Utopia Parkway, Queens, NY 11439 (charnesl{at}stjohns.edu).


Purpose. A case of lamotrigine-induced Stevens-Johnson syndrome (SJS) is reported.

Summary. A 29-year-old woman with a medical history of schizoaffective disorder arrived at the emergency department with a severe generalized skin reaction. Three to four days prior she had noticed bumps on her lips that had spread to her oral mucosa. She had also developed a diffuse, erythematous, pruritic full-body rash involving the palms of her hands and the soles of her feet and began to feel feverish. Her medications at admission included aripiprazole 30 mg p.o. daily, escitalopram 10 mg p.o. daily, and lamotrigine 75 mg p.o. daily. Lamotrigine was the only new medication, initiated four weeks before this admission. The dermatology service confirmed the diagnosis of SJS using punch biopsy. Lamotrigine was suspected to be the culprit and was discontinued immediately. The patient was given oral prednisone 40 mg and intravenous fluids. Hydroxyzine was given for pruritis, and petroleum jelly and viscous lidocaine were applied to her lips. On hospital day 2, her symptoms and dermatological manifestations improved, but she continued to complain about irritation and slight pain of the mouth. She then received a mouthwash consisting of diphenhydramine, viscous lidocaine, and sodium bicarbonate. On hospital day 3, the patient had improved substantially and was discharged home. Reports of these dermatological reactions in patients receiving lamotrigine for the treatment of bipolar disorder are limited. Dosing, prompt recognition, and patient education are crucial for preventing morbidity and mortality associated with the development of serious cutaneous reactions.

Conclusion. SJS was associated with lamotrigine use, despite appropriate dosing and dosage adjustment.

Index terms: Alkalinizing agents; Anesthetics, local; Anticonvulsants; Antihistamines; Aripiprazole; Diphenhydramine; Dosage; Escitalopram; Hydroxyzine; Lamotrigine; Lidocaine; Lubricants; Patient information; Petrolatum; Prednisone; Sodium bicarbonate; Steroids, cortico-; Stevens-Johnson syndrome; Toxicity

 






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society of Health-System Pharmacists.